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Chronic obstructive pulmonary disease (COPD) shows progressive, irreversible airﬂow limitation induced
by emphysema and lung inﬂammation. The aim of the present study was to determine if COPD condi-
tions induce bloodebrain barrier (BBB) dysfunction. We found that the intratracheal administration of
porcine pancreatic elastase (PPE; 3 U) induced alveolar enlargement, increased neutrophil number in
bronchoalveolar lavage ﬂuid, and decreased blood oxygen saturation in mice at 21 days after inhalation.
In parallel with these lung damages, BBB permeability to sodium ﬂuorescein and Evans blue albumin was
markedly increased. Our ﬁndings demonstrate that COPD conditions are associated with risk for BBB
impairment.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Chronic obstructive pulmonary disease (COPD) shows progres-
sive and irreversible airﬂow limitation with emphysema and lung
inﬂammation. In addition to a systemic inﬂammatory component,
neuropsychiatric symptoms including anxiety, depression, and
cognitive impairment occur in COPD patients (1). The bloodebrain
barrier (BBB), an interface between the central nervous system and
peripheral blood circulation, maintains brain milieu and limits
entry of blood-derived neurotoxic proteins including therapeutic
drugs (2). Impairment of the BBB occurs under several peripheral
inﬂammatory diseases and allows transfer of BBB-impermeable
drugs into the brain, causing drug-associated neurotoxicity (3).
Dysregulation of BBB integrity precedes the onset of neuro-
degeneration, suggesting that brain damage develops in association
with BBB impairment. Under these conditions, the brain is
considered to become vulnerable to the central adverse reactions of
drugs (2,4). COPD patients are prescribed muscarinic antagonists,
b2-agonists, and phosphodiesterase-4 inhibitors to improve airﬂowical Care and Health Sciences,
ty, 8-19-1 Nanakuma, Jonan-
fax: þ81 92 862 2699.
oka).
rmacological Society.
Production and hosting by Elsevie
ons.org/licenses/by-nc-nd/4.0/).obstruction, and varenicline for smoking cessation (5,6). In addi-
tion, they often require several drugs for other diseases, particularly
elderly COPD patients. Thus, COPD patients are at high risk of
central adverse drug reactions. For example, inhaled b2-agonists
can cause headaches, tremors, and agitation (7). However, COPD-
induced BBB alterations have remained obscure. Here, to clarify
BBB pathophysiology under COPD conditions, we generated a COPD
mouse model by intratracheal administration (i.t.) of porcine
pancreatic elastase (PPE) according to the method previously re-
ported by Kurimoto et al. (8) and subsequently examined BBB
permeability in COPD mice.
All procedures involving experimental animals adhered to the
Law (No. 105) and Notiﬁcation (No. 6) of the Japanese Government,
and were approved by the Laboratory Animal Care and Use Com-
mittee of Fukuoka University. C57BL/6 mice (Clea Japan Inc., Tokyo,
Japan), aged 7 weeks, were anesthetized by intraperitoneal injec-
tion of pentobarbital (50 mg/kg i.p.), followed by a spray of 0.3 or
3 U PPE (Sigma, St. Louis, MO, USA) dissolved in 25 mL sterile
phosphate-buffered saline (PBS) or 25 mL PBS alone (vehicle group)
into the trachea using a MicroSprayer drug delivery device (Penn-
Century Inc., Philadelphia, PA, USA). Twenty-one days after PPE or
PBS i.t., mice were sacriﬁced to harvest tissue under anesthesia.
Lungs were perfused with PBS (0.4 mL 4) and bronchoalveolar
lavage ﬂuid (BALF) was collected from each mouse. BALF wasr B.V. on behalf of Japanese Pharmacological Society. This is an open access article
F. Takata et al. / Journal of Pharmacological Sciences 129 (2015) 78e81 79immediately centrifuged at 1000 g for 10 min at 4 C, and after
lysing red blood cells in Red Blood Cell Lysing Buffer (Sigma), the
cell pellets were resuspended in PBS (100 mL). Neutrophils in BALF
were identiﬁed by Giemsa staining, and cell numbers were counted
under a standard light microscope. After perfusionwith PBS and 8%
formalin through the left cardiac ventricle, lung tissue was
collected from the superior lobe of the left lung in each mouse and
stored in formalin for 48 h. Serial sections (7 mm thick) of the lung
were prepared and stained with hematoxylin and eosin (H&E).
Lung images were obtained using a Keyence BZ-X710 microscope
(Keyence Corporation, Osaka, Japan), and the distance between
alveolar walls in randomly selected areas was measured using
ImageJ software (http://rsb.info.nih.gov/). The averaged linear
intercept of alveoli was obtained from 3 or 4 non-overlapping
microscopic ﬁelds per section in three different sections (10
ﬁelds) from each mouse. Oxygen saturation (SpO2) was recorded
using a pulse oximeter under anesthesia (PowerOxy900; Bio
Research Center, Nagoya, Japan).
An in vivo BBB permeability test was performed as described
previously (9). In brief, PBS (150 mL) containing sodium ﬂuorescein
(Na-F) (2 mg/mL; Sigma) and Evans blue (EB) (20 mg/mL; Sigma)
was injected into the jugular vein under anesthesia. Thirty minutes
after intravenous injection, blood was collected from the right
atrium and centrifuged at 1000 g for 10 min at 4 C. Mice were
perfused with PBS and then decapitated. The whole brain was
removed and weighed. Brains and serum were homogenized in
0.5 M borate buffer (pH 10) and centrifuged at 800 g for 15 min at
4 C. Supernatants were mixed with ethanol and then centrifuged
(15,000 g) for 20 min at 4 C. Supernatant Na-F and EBFig. 1. PPE inhalation-induced damage to lung morphology and function. Histological observ
Representative photographs show H&E-stained lung sections at 21 days after vehicle, 0.
enlargement at 21 days after inhalation. The mean linear intercept of alveoli in H&E-stain
Arterial oxygen saturation at 21 days after vehicle and 3 U PPE inhalation (n ¼ 10e11 mice
vehicle. yP < 0.05, signiﬁcantly different from 0.3 U PPE.concentrations were determined as described previously (10). The
brain/serum ratio was calculated according to the method
described by Abraham et al. (11), and was expressed as microliters
of tracer diffusing from the blood to brain per grams of brain.
Graph Pad Prism 5.0 (GraphPad, San Diego, CA, USA) was used to
perform all statistical analyses. Results are shown asmeans ± S.E.M.
The Student's t-test was used for comparison of neutrophil
numbers and SpO2. Other data were assessed by one-way analysis
of variance, followed by TukeyeKramer's test for multiple com-
parisons. Differences were considered signiﬁcant with P values
<0.05.
As shown in Fig. 1A, H&E-stained histological sections revealed
normal lung structure in the vehicle group. Moreover, no patho-
logical changes were observed between vehicle and 0.3 U PPE
treatment. However, with 3 U PPE inhalation, mice developed
signiﬁcant alveolar enlargement compared with vehicle- and 0.3 U
PPE-treated mice (n ¼ 5 mice per group, P < 0.05 versus vehicle or
0.3 U PPE) (Fig. 1B). The neutrophil number in BALF at 21 days after
PPE inhalation was determined, with 5481 ± 939 and
8757 ± 1200 cells/mL in vehicle- and 3 U PPE-inhaled mice (60%
increase), respectively (n ¼ 7e8 mice per group, P < 0.05 versus
vehicle). SpO2 signiﬁcantly decreased with 3 U PPE to 93.5 ± 1.5% of
vehicle at 21 days after inhalation (n ¼ 10e11 mice per group,
P < 0.05 versus vehicle) (Fig. 1C). PPE at 3 U (but not 0.3 U)
signiﬁcantly increased BBB permeability for Na-F (MW 376) and EB
albumin (EBA) (MW 67,000) in mouse brain (28.2 ± 6.7 and
54.8 ± 16.0% increase, respectively) (n ¼ 10e19 mice per group,
P < 0.05 versus vehicle) (Fig. 2).ation of lung tissue and blood gas analysis were performed at 21 days after PPE i.t. (A)
3 U PPE, and 3 U PPE inhalation (n ¼ 5 mice per group). (B) PPE-induced alveolar
ed lung sections was calculated in each mouse. Each bar indicates mean ± S.E.M. (C)
per group). Data are expressed as mean ± S.E.M. *P < 0.05, signiﬁcantly different from
AB
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Fig. 2. PPE inhalation produces BBB hyperpermeability in mice. The relative brain/
serum ratios of Na-F (A) and EBA (B) were expressed as a percentage of the value of the
vehicle-inhaled mice at 21 days after vehicle, 0.3 U PPE, and 3 U PPE i.t. (n ¼ 10e19
mice per group). Each bar indicates mean ± S.E.M. *P < 0.05, signiﬁcantly different
from vehicle. yP < 0.05, signiﬁcantly different from 0.3 U PPE. The absolute values
(mean ± S.E.M) of vehicle-, 0.3 U-, and 3 U-inhaled mice for Na-F (A) were
9.17  105 ± 2.16  106, 8.34  105 ± 3.27 106, and 1.07 104 ± 3.38  106 mg/
mg (brain), 3.31 ± 0.14, 3.31 ± 0.20, and 3.03 ± 0.23 mg/mL (serum), and
2.84  105 ± 9.81  107, 2.55  105 ± 6.63  107, and 3.64  105 ± 1.81  106 mL/
mg (brain/serum ratio), respectively. The absolute values of vehicle-, 0.3 U-, and 3 U-
inhaled mice for EBA (B) were 2.86  103 ± 6.29  105, 3.50  103 ± 1.16  104,
and 3.99  103 ± 2.13  104 mg/mg (brain), 1206 ± 46, 1487 ± 42, and 1136 ± 112 mg/
mL (serum), and 2.44  106 ± 1.03  107, 2.37  106 ± 1.01  107, and
3.78  106 ± 3.69  107 mL/mg (brain/serum ratio), respectively.
F. Takata et al. / Journal of Pharmacological Sciences 129 (2015) 78e8180Here, we have established a COPD mouse model by PPE i.t.,
which shows moderate lung architecture damage, with enlarged
pulmonary alveoli, neutrophil inﬁltration in the lung, and lowered
blood oxygen saturation. In parallel with this COPD-simulated lung
pathophysiology, BBB hyperpermeability for Na-F and EBA
occurred, suggesting that BBB permeability for blood-derived
substances increases under COPD conditions. The molecular
weight of Na-F is similar to that of commonly used medicines.
Permeability of EBA implies albumin delivery into the brain.
Therefore, COPD likely increases transfer of BBB-impermeable
drugs and blood-borne proteins, such as albumin, thrombin, and
ﬁbrin, through the BBB into the brain parenchyma. This phenom-
enon may lead to increased risk for unexpected central adverse
drug reactions and pathogenic protein-induced neurodegeneration
in the brain under COPD conditions. In support of this notion, our
previous study found that acute liver failure increases BBB
permeability to cyclosporin A, a drug that is less BBB permeable, by
reducing P-glycoprotein and tight junctions, consequently leading
to exacerbation of cyclosporin A-induced neurotoxicity (3). In
addition, BBB breakdown leads to leakage of blood-borne proteins
into the brain parenchyma. Brain accumulation of these proteins
can cause cerebral edema, neurodegeneration, and memory
impairment (2,12). Therefore, COPD conditions appear to be highlyvulnerable to neurovascular damage. Indeed, COPD patients are
prone to neuropsychiatric symptoms including cognitive impair-
ment (1). A muscarinic antagonist is well known to increase risk for
inducing and/or exacerbating cognitive impairment (13). However,
it remains to be determined whether an inhaled long-acting
muscarinic antagonist commonly used in COPD patients aggra-
vates cognitive and affective symptoms in these patients. This
should be addressed in future studies. Taken together with our
present ﬁndings, the possibility that COPD induces BBB breakdown
has to be considered in drug therapy recommendations for COPD
patients.
We found that PPE inhalation in mice results in alveolar
enlargement and neutrophil inﬁltration, and decreased blood ox-
ygen levels. These are consistent with COPD patients (14,15). Based
on evidence that hypoxic conditions produce BBB dysfunction (10),
Low blood oxygen levels caused by lung dysfunction likely con-
tributes to induction and/or development of BBB hyper-
permeability in PPE-inhaled mice. Inﬂammation-associated
substances are increased in the blood of COPD patients (16).
Exposure of these substances to the BBB lowers BBB function (11).
Altogether, increased and decreased blood levels of proin-
ﬂammatory cytokines/chemokines and oxygen, respectively,
induced by pulmonary dysfunction, likely contribute to formation
of BBB pathophysiology under COPD conditions.Conﬂicts of interest
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